Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC - Full Text View - ClinicalTrials.gov
Diphosphonates. Antineoplastic Agents. Protein Kinase Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of Pharmacological ...https://clinicaltrials.gov/ct2/show/NCT01259193
Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis - Full...
Patients with lung cancer and bone metastatic disease may experience moderate or severe bone pain. Some researches have reported that loading doses Bondronat (6mg Bondronat on three consecutive days) had great efficacy in reducing pain in patients with malignant bone disease without unacceptable toxicities. So,we designed this clinical trial to compare the efficacy and safety profiles between loading doses Bondronat and standard dose Bondronat.Enrolled patients will receive an intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day. The targeted sample size is 120 individuals. Primary outcome measures will be bone pain response ( ≥ 25% decrease in mean pain score with a maximum of 15% increase in mean analgesic consumption). Secondary outcome measures will be efficacy including ECOG Performance status, analgesic consumption, bone markers, and safety profiles including AE and laboratory parameters ...https://clinicaltrials.gov/ct2/show/NCT00492843
Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. - The Kennedy Institute...
Diphosphonates, Female, Fractures, Bone, Hip Fractures, Humans, Incidence, Male, Middle Aged, Patient Compliance, Proton Pump ...https://www.kennedy.ox.ac.uk/publications/407858
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone...
PRIMARY OBJECTIVES:. I. To determine whether every-12-week therapy with zoledronic acid is not inferior to every-4-week therapy for patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma involving bone, as measured by the proportion who experience at least one skeletal related event within 24 months after randomization.. SECONDARY OBJECTIVES:. I. To compare pain scores (Brief Pain Inventory) of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing.. II. To compare the functional status (Eastern Cooperative Oncology Group [ECOG] performance status) of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing.. III. To compare the incidence of osteonecrosis of the jaw in patients with metastatic breast cancer, ...https://clinicaltrials.gov/ct2/show/NCT00869206
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. - Nuffield Department of...
Spine, Humans, Osteoporosis, Postmenopausal, Spinal Fractures, Diphosphonates, Collagen, Collagen Type I, Peptides, ...https://www.ndorms.ox.ac.uk/publications/126429
Parathyroid Hormone Effects in Rats Treated with Diphosphonate | Science
Parathyroid Hormone Effects in Rats Treated with Diphosphonate Message Subject. (Your Name) has forwarded a page to you from ... The ability of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP; 40 milligrams per kilogram of body weight per day) to reduce ...http://science.sciencemag.org/content/183/4125/661
Diphosphonate | definition of diphosphonate by Medical dictionary
... diphosphonate explanation free. What is diphosphonate? Meaning of diphosphonate medical term. What does diphosphonate mean? ... Looking for online definition of diphosphonate in the Medical Dictionary? ... diphosphonate. Also found in: Dictionary, Wikipedia. diphosphonate. [di-fos´fo-nāt] any of a group of related phosphorus- ... diphosphonate. /di·phos·pho·nate/ (di-fos´fŏ-nāt) 1. a salt, ester, or anion of a dimer of phosphonic acid, structurally ...http://medical-dictionary.thefreedictionary.com/diphosphonate
Idiopathic infantile arterial calcification in two siblings: failure of treatment with diphosphonate. | Heart
Idiopathic infantile arterial calcification in two siblings: failure of treatment with diphosphonate. ... Idiopathic infantile arterial calcification in two siblings: failure of treatment with diphosphonate. ...http://heart.bmj.com/content/64/2/156
Mixed-solvothermal synthesis, structures, luminescent and surface photovoltage properties of four new transition metal...
... diphosphonates with a 3D supramolecular structure, M(hedpH2)3·3NH2(CH3)2NH(CH3)3·3H2O (M = Mn (1), Co (2), Ni (3), Zn (4); ... Four new transition metal(II) diphosphonates with a 3D supramolecular structure, M(hedpH2)3·3NH2(CH3)2NH(CH3)3·3H2O (M = Mn (1 ... structures, luminescent and surface photovoltage properties of four new transition metal diphosphonates with a 3D ... structures, luminescent and surface photovoltage properties of four new transition metal diphosphonates with a 3D ...http://pubs.rsc.org/en/content/articlelanding/2012/nj/c2nj40737j
The rational design, synthesis and demonstration of the recognition and binding of a diaza-dioxa-12-crown-4 diphosphonate...
The rational design, synthesis and demonstration of the recognition and binding of a diaza-dioxa-12-crown-4 diphosphonate ... The rational design, synthesis and demonstration of the recognition and binding of a diaza-dioxa-12-crown-4 diphosphonate ...http://pubs.rsc.org/en/Content/ArticleLanding/2002/P2/b203285f
186Re-labeled HEDP4 and 153Sm-labeled EDTMP are radioactive metal diphosphonates (6, 7, 8, 9, 10) in which bone localization is ... Imaging studies included a radionuclide bone scan performed with 99mTc-labeled methylene diphosphonate. Patients with symptoms ... A similar dissociation has been observed with low-dose corticosteroids, cold diphosphonates, and the bone resorption inhibitor ... Rhenium-186 (tin)-labeled hydroxyethylidene diphosphonate (186Re-labeled HEDP) was evaluated in 27 men with progressive ...http://clincancerres.aacrjournals.org/content/5/6/1307
Objective. We introduce the use of 99mTc-hydroxymethylene diphosphonate (HDP) digital blood flow scintigraphy to diagnose ... Diagnosis of Raynaud's Phenomenon by 99mTc-Hydroxymethylene Diphosphonate Digital Blood Flow Scintigraphy After One-hand ... Diagnosis of Raynaud's Phenomenon by 99mTc-Hydroxymethylene Diphosphonate Digital Blood Flow Scintigraphy After One-hand ... Diagnosis of Raynaud's Phenomenon by 99mTc-Hydroxymethylene Diphosphonate Digital Blood Flow Scintigraphy After One-hand ...http://www.jrheum.org/content/36/8/1663
Trisodium hydrogen[[(3,5,5-trimethylhexyl)imino]bis(methylene)]diphosphonate - Alfa Chemistry
... diphosphonate/ACM94201997 can be provided in Alfa Chemistry. We are dedicated to provide our customers the best products and ... Home > Product > Heterocyclic Organic Compound > Trisodium hydrogen[[(3,5,5-trimethylhexyl)imino]bis(methylene)]diphosphonate ... Trisodium hydrogen[[(3,5,5-trimethylhexyl)imino]bis(methylene)]diphosphonate , CAS Number: 94201-99-7. ...http://www.alfa-chemistry.com/cas_94201-99-7.htm
Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment. - Nuffield Department of...
Experience with a diphosphonate (disodium etidronate) in treatment. Share Share Share Share ...https://www.ndorms.ox.ac.uk/publications/109118
Do Tc-99m-diphosphonate bone scans have any place in the investigation of polyarthralgia? - Nuffield Department of Orthopaedics...
Do Tc-99m-diphosphonate bone scans have any place in the investigation of polyarthralgia? Share Share Share Share ... Do Tc-99m-diphosphonate bone scans have any place in the investigation of polyarthralgia? ...https://www.ndorms.ox.ac.uk/publications/227290
Use of bisphosphonates and reduced risk o... & related info | Mendeley
(2011) Rennert et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. PURPOSE: Bisphosphonates are commonly used for the treatment of osteoporosis and bone metastases caused by breast cancer and were recently reported to be associated with a reduced risk of breast ca...https://www.mendeley.com/research-papers/bisphosphonates-reduced-risk-colorectal-cancer-1/
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer - Full Text View - ClinicalTrials.gov
The purpose of this research study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases. The blood test will look for a protein, called TRAP, which is released into the blood stream by the breakdown of bone. This study will compare the TRAP blood test with other blood tests for bone destruction ...https://clinicaltrials.gov/ct2/show/NCT00265200
Zometa Study in Pediatric Acute Lymphoblastic Leukemia - Full Text View - ClinicalTrials.gov
Diphosphonates. Micronutrients. Growth Substances. Physiological Effects of Drugs. Bone Density Conservation Agents. ...https://clinicaltrials.gov/ct2/show/NCT01656512
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma - Full Text View -...
Diphosphonates. Bone Density Conservation Agents. Additional relevant MeSH terms: Multiple Myeloma. Neoplasms, Plasma Cell. ...https://clinicaltrials.gov/ct2/show/NCT01345019?recr=Open&cond=%22Bone+Marrow+Diseases%22&rank=19
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases - Full Text View -...
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...https://clinicaltrials.gov/ct2/show/NCT00434317
Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation - Full Text View -...
Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res. 1984 Jul;44(7):3007-11. ... Adami S, Salvagno G, Guarrera G, Bianchi G, Dorizzi R, Rosini S, Mobilio G, Lo Cascio V. Dichloromethylene-diphosphonate in ... Effects of intravenous diphosphonates on renal function. Lancet. 1983 Jun 11;1(8337):1328. ... Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. Br Med J ( ...https://clinicaltrials.gov/show/NCT00264420
18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone - Full Text View - ClinicalTrials.gov
Diphosphonates. Cariostatic Agents. Protective Agents. Physiological Effects of Drugs. Bone Density Conservation Agents. ...https://clinicaltrials.gov/ct2/show/NCT00306046?term=paget
Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients'...
The lower bone mineral density that has been described in patients with HIV-infection has not meant an increase of long term complications. Nevertheless, it could involve an increase if the associated co-morbidity in the future, taking in care that in general population osteoporosis increases 4 times the pathologic fracture risk. That is why it is necessary to know the real prevalence of osteoporosis in this population of patients so the real dimensions of the problems can be defined.. This project wills to determine the incidence of osteoporosis in our population of HIV-infected patients and to assess the efficacy and security of zoledronic acid. If the annual use of endovenous zoledronic acid obtains equivalent results to those obtained with oral and weekly alendronate in other studies with the same population, its use would be justified because of its posology benefits. The annual administration can improve compliance in patients who are receiving a big quantity of drugs, as HIV-infected ...https://clinicaltrials.gov/ct2/show/NCT00795483?term=paget
Bisphosphonate Therapy for Osteogenesis Imperfecta - Full Text View - ClinicalTrials.gov
The study is designed to evaluate the efficacy and safety of 'Bisphosphonate Therapy for Osteogenesis Imperfecta (OI).' OI is an inherited disorder of collagen synthesis. Collagen is the major structural protein of the matrix of tendons, skin, and bones. Affected persons have low bone mineral density (and experience multiple fractures and progressive bony deformity). In its most severe form, the disorder is lethal in infancy. We plan to characterize the changes effected by oral bisphosphonate therapy and compare them to a regimen of intravenous bisphosphonate therapy in a group of children with OI.. Additionally, we have begun to treat patients with OI and other conditions of low bone mineralization for age who are not eligible for the standard protocol (too young, history of abdominal pain, etc.) with bisphosphonate. We also plan to screen the parents and siblings of our patients diagnosed with osteogenesis imperfecta, in order to determine if they also have osteoporosis. ...https://clinicaltrials.gov/ct2/show/NCT00159419?cond=%22Osteogenesis+Imperfecta%22&rank=5